Does Parkinsons Disease Dementia Reduce Cancer Risk more than Alzheimers Disease Alone?
نویسندگان
چکیده
منابع مشابه
Early-versus late-onset Alzheimer's disease: more than age alone.
Alzheimer's disease (AD) is the most common cause of dementia at older age. Although less prevalent before the age of 65 years, it is still the most frequent cause of early-onset dementia followed by frontotemporal dementia. The typical presentation of AD is memory dysfunction, however, presentations with prominent cognitive impairment in other domains besides memory, like prominent apraxia, la...
متن کاملOrbitofrontal Dysfunction Discriminates Behavioral Variant Frontotemporal Dementia from Alzheimers Disease
Background: Behavioral variant frontotemporal dementia (bvFTD) patients show prefrontal cortex dysfunction and atrophy. Methods: We investigated whether executive function in conjunction with prefrontal cortex atrophy discriminates bvFTD and Alzheimer’s disease (AD) patients efficiently at presentation. Results: AD and bvFTD patients were distinguishable by 89.5% on their performance of 3 execu...
متن کاملLaw more than 80 % A strategy to reduce cardiovascular disease
Objectives To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects. The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function) regardless of pretrea...
متن کاملA strategy to reduce cardiovascular disease by more than 80%.
OBJECTIVES To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects. The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function) regardless of pretrea...
متن کاملMore than technology alone.
Traditionally, developments in the labon-a-chip community have been technology-pushed, mainly guided by analytical chemists, micro-machinists and material scientists, rather than demand-pulled. Applications such as LabChip from Caliper (Fig. 1) and i-STAT from Abbott Point of Care (Fig. 2) can now be found on the market, solving practical problems for users. However, the field is still lacking ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuropsychiatry
سال: 2018
ISSN: 1758-2008
DOI: 10.4172/neuropsychiatry.1000222